StockData
Replimune Group, Inc. logo

Replimune Group, Inc. (REPL) balance sheet

REPLNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends March 31
Số liệu tài chính tới Q2 năm tài chính 2027, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q/A on Nov 6, 2026Score 1/30
$19.81+0.12 (+0.61%)

Close on Nov 18, 2026Market cap $1.88BP/E –Yield –

Replimune Group, Inc. balance sheet

Ratios

Latest available, balances at Sep 30, 2026

Profitability, FY

Gross margin
–
Operating margin
–
Net margin
–
Return on equity, FY2026
-107.9%

Financial strength

Current ratio
7.11
Debt to equity
0.49
Debt to assets
26.7%
Cash to current liabilities
675.8%

Valuation

P/E ratio
–
Price to sales
–
Price to book
9.17
Dividend yield
–

See a number that looks wrong?